BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32053767)

  • 1. Precision medicine in gastrointestinal stromal tumors.
    Florou V; Trent JC; Wilky BA
    Discov Med; 2019; 28(155):267-276. PubMed ID: 32053767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ripretinib for the treatment of advanced gastrointestinal stromal tumor.
    Zalcberg JR
    Therap Adv Gastroenterol; 2021; 14():17562848211008177. PubMed ID: 33948116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current research and treatment for gastrointestinal stromal tumors.
    Lim KT; Tan KY
    World J Gastroenterol; 2017 Jul; 23(27):4856-4866. PubMed ID: 28785140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors.
    Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P
    Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastrointestinal Stromal Tumors: What Is the Best Sequence of TKIs?
    Senchak J; Ahr K; von Mehren M
    Curr Treat Options Oncol; 2022 May; 23(5):749-761. PubMed ID: 35349049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy.
    Wardelmann E; Büttner R; Merkelbach-Bruse S; Schildhaus HU
    Virchows Arch; 2007 Oct; 451(4):743-9. PubMed ID: 17701051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors.
    Nishida T; Doi T; Naito Y
    Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
    Franck C; Rosania R; Franke S; Haybaeck J; Canbay A; Venerito M
    Digestion; 2019; 99(2):179-184. PubMed ID: 30179868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of KIT in the management of patients with gastrointestinal stromal tumors.
    Hornick JL; Fletcher CD
    Hum Pathol; 2007 May; 38(5):679-87. PubMed ID: 17437861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Type I and II tyrosine kinase inhibitors-avapritinib and sunitinib-in refractory gastrointestinal stromal tumor after failure to multi-line therapy: a case report.
    Guo X; Huang S; Shi Y; Guan Z; Chen S; Feng Y; Xia Y; Zhang X
    Ann Transl Med; 2022 Sep; 10(18):1026. PubMed ID: 36267752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Activating mutations in receptor tyrosine kinases with relevance for treatment of gastrointestinal stromal tumors].
    Wardelmann E; Merkelbach-Bruse S; Büttner R; Schildhaus HU
    Verh Dtsch Ges Pathol; 2007; 91():165-8. PubMed ID: 18314611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rhabdomyosarcomatous differentiation in gastrointestinal stromal tumors after tyrosine kinase inhibitor therapy: a novel form of tumor progression.
    Liegl B; Hornick JL; Antonescu CR; Corless CL; Fletcher CD
    Am J Surg Pathol; 2009 Feb; 33(2):218-26. PubMed ID: 18830121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Revolutions in treatment options in gastrointestinal stromal tumours (GISTs): the latest updates.
    Farag S; Smith MJ; Fotiadis N; Constantinidou A; Jones RL
    Curr Treat Options Oncol; 2020 May; 21(7):55. PubMed ID: 32462367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ripretinib for the treatment of advanced, imatinib-resistant gastrointestinal stromal tumors.
    Liu WZ; Du YQ; Shen Q; Tao KX; Zhang P
    J Dig Dis; 2023 Sep; ():. PubMed ID: 37706279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gastrointestinal stromal tumors (GISTs): from science to targeted therapy.
    Sarmiento R; Bonginelli P; Cacciamani F; Salerno F; Gasparini G
    Int J Biol Markers; 2008; 23(2):96-110. PubMed ID: 18629782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours.
    Lasota J; Miettinen M
    Histopathology; 2008 Sep; 53(3):245-66. PubMed ID: 18312355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New frontiers in the medical management of gastrointestinal stromal tumours.
    Mazzocca A; Napolitano A; Silletta M; Spalato Ceruso M; Santini D; Tonini G; Vincenzi B
    Ther Adv Med Oncol; 2019; 11():1758835919841946. PubMed ID: 31205499
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Molecular Subtypes for Precision Therapy of Recurrent and Metastatic Gastrointestinal Stromal Tumor.
    Liu P; Tan F; Liu H; Li B; Lei T; Zhao X
    Onco Targets Ther; 2020; 13():2433-2447. PubMed ID: 32273716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.